Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data

Schizophrenia Research

Volumn 137, Issue 1-3, 2012, Pages 147-150

  Rabinowitz, Jonathan ^a   Levine, Stephen Z ^b   Garibaldi, George ^c   Bugarski Kirola, Dragana ^c   Berardo, Carmen Galani ^c   Kapur, Shitij ^d  

^a BAR ILAN UNIVERSITY   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Negative; Outcomes; Positive; Schizophrenia; Symptoms

Indexed keywords

OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CALGARY DEPRESSION RATING SCALE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL ASSESSMENT; HEINRICH'S AND LEHMAN'S QUALITY OF LIFE SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOCIAL INTERACTION; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84860834493     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.01.015     Document Type: Article

References (15)

1. Addington D., Addington J., Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr. Res. 1994, 11(3):239-244.
2. Heinrichs D.W., Hanlon E.T., Carpenter W.T. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10:388-398.
3. Herbener E.S., Harrow M. Are negative symptoms associated with functioning deficits in both schizophrenia and nonschizophrenia patients? A 10-year longitudinal analysis. Schizophr. Bull. 2004, 30(4):813-825.
4. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):214-219.
5. Leber P. Regulatory issues. Neuropsychopharmacology: The Fifth Generation of Progress 2002, 485-494. Lippincott, Philadelphia. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
6. Lehman A.F. The quality of life interview for the severe mentally ill. Eval. Program Plann. 1988, 11:51-62.
7. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
8. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58(12):538-546.
9. McGurk S.R., Moriarty P.J., Harvey P.D., Parrella M., White L., Friedman J., Davis K.L. Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients. J. Neuropsychiatry Clin. Neurosci. 2000, 12(2):257-264.
10. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 2005, 162(3):495-506.
11. Mohamed S., Rosenheck R., Swartz M., Stroup S., Lieberman J.A., Keefe R.S. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am. J. Psychiatry 2008, 165(8):978-987.
12. Rocca P., Montemagni C., Castagna F., Giugiario M., Scalese M., Bogetto F. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(2):373-379.
13. Strauss J.S., Carpenter W.T. The prediction of outcome in schizophrenia. I. Characteristics of outcome. Arch. Gen. Psychiatry 1972, 27(6):739-746.
14. Swartz M.S., Perkins D.O., Stroup T.S., McEvoy J.P., Nieri J.M., Haak D.C. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr. Bull. 2003, 29(1):33-43.
15. Tabachnick B.G., Fidell L.S. Using Multivariate Statistics 2001, 131. Harper & Collins, NY. 4 ed.